AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth

, /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 17, 2025, the company's performance in 2024 showed a significant reduction in losses. Preliminary assessments indicate that the company's revenue is expected to be between RMB 1.25 billion and RMB 1.3 billion, representing a growth of 5% to 9% compared to the previous year. The net loss is projected to be between RMB 250 million and RMB 290 million, which is a reduction of 85% to 87% compared to the previous year, marking a substantial decrease in losses. The board of directors preliminarily believes that the increase in revenue is mainly due to the growth in sales of the hepatitis B vaccine, while the reduction in net losses is primarily attributed to a decrease in significant asset impairment losses this year and the increase in revenue.

AIM Vaccine's significant reduction in losses for 2024 and growth in sales revenue indicate that the company has entered an upward turning point. A recent research report by Fosun International suggests that the company's core products, the hepatitis B vaccine and the rabies vaccine, are expected to enter a stable growth phase in 2025. Additionally, new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine, as well as mRNA-based respiratory syncytial virus and shingles vaccines, are expected to launch in the next 2-3 years, driving the company toward leapfrog development and value re-evaluation.

According to research from SDIC Securities Co., Ltd, AIM Vaccine is expected to launch 1-2 products each year over the next three years. If the products under development are successfully approved for market entry and progress smoothly in international markets, this is likely to bring new growth points for the company and open up market potential.

Just last week, the company announced that its serum-free rabies vaccine has recently obtained a production license and will be submitted for drug market registration. This product is expected to become the world's first serum-free rabies vaccine on the market. Additionally, last November, another major product, the 13-valent pneumococcal conjugate vaccine, also obtained the corresponding production license and has officially submitted for drug market registration.

According to Fosun International Securities' forecast, the compound annual growth rate of AIM Vaccine's revenue from 2024 to 2027 is expected to reach 47%. The company is anticipated to achieve breakeven in 2025, and by 2027, net profits are expected to exceed RMB 1.52 billion. Considering AIM Vaccine's strong research and development capabilities, technological advantages, and potential for international market expansion, Fosun International Securities has given AIM Vaccine a "Buy" rating, with a target price of 11 HKD.